Ancillary Studies to Large Ongoing Clinical Projects (R21)

The summary for the Ancillary Studies to Large Ongoing Clinical Projects (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Ancillary Studies to Large Ongoing Clinical Projects (R21): Purpose. This Funding Opportunity Announcement (FOA) solicits applications that propose to conduct time-sensitive ancillary studies that are exploratory/developmental and highly innovative in nature and related to the NIAMS mission in conjunction with privately or publicly funded, large, ongoing clinical projects. The ongoing parent project can be a large clinical trial or observational study, or a disease registry that can provide a sufficient cohort of well-characterized patients, infrastructure, data, and biological samples. Applications submitted in response to this FOA will undergo an accelerated review and award process. Each application must include a timeline to demonstrate that the parent project has adequate time left to accommodate the proposed ancillary study. In addition, it must justify the time-sensitive nature of the ancillary study and the need for an expedited review and award process. It must also document permission from the parent project to use the patient cohorts, data and biological materials. The objective of this FOA is to provide a flexible mechanism to leverage established resources and maximize the return on the existing investments in parent projects. Successful ancillary studies will enhance the scientific content and value of the parent projects, improve the research communitys understanding of a disease or organ system in the NIAMS portfolio, and thus identify novel targets for diagnosis, treatment and prevention of disease. Mechanism of Support. This FOA will utilize the NIH Exploratory/Developmental Grant (R21) award mechanism and runs in parallel with another FOA of identical scientific scope, RFA-AR-10-010, which encourages applications under the NIH Research Grant (R01) award mechanism. Funds Available and Anticipated Number of Awards. The NIAMS expects to commit approximately $1.5 million total costs in FY2011 to support a total of four to six new awards combined from the two parallel FOAs for R01s (RFA-AR-11-012) and R21s (RFA-AR-11-013). Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

Federal Grant Title:	Ancillary Studies to Large Ongoing Clinical Projects (R21)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-AR-11-013
Type of Funding:	Grant
CFDA Numbers:	93.846
CFDA Descriptions:	Arthritis, Musculoskeletal and Skin Diseases Research
Current Application Deadline:	Apr 01, 2011
Original Application Deadline:	Apr 01, 2011
Posted Date:	Sep 01, 2010
Creation Date:	Sep 01, 2010
Archive Date:	May 02, 2011
Total Program Funding:	$1,500,000
Maximum Federal Grant Award:	$200,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 ...; • Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 ...; • Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) (P50 Cli...; • Core Centers for Clinical Research (CCCR) (P30 Clinical Trial Not Allowed); • NIAMS Skin Biology and Diseases Resource-based Centers (P30 - Clinical Trial Not Allowed); • Collaborative Arthritis and Musculoskeletal and Skin Diseases Science Award (Camssa); • Niams Small Grant Program for New Investigators; • Skin Diseases Research Core Centers
More Grants from the National Institutes of Health: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...